CS-070failure
International Business Machines Corporation (IBM)
IBM Watson Health: AI and data in health care, from formation to the sale of its assets (2015–2022)
- Region
- North America, Global
- Country
- United States
- Industry
- Medical and Health Technology (Discrete Manufacturing)
- Functions
- Data, Analytics & AI, Product, R&D & Innovation, Strategy, Corporate Development & Transformation Office, IT, ERP & Digital
- Topics
- AI investments are not delivering measurable value; Investment capital is not generating returns; Technology spending is growing without business returns; Data cannot be trusted for critical decisions
- Starting situation
- New initiative
- Period
- 2015–2022
- Last verified
- 1 November 2026
Executive summary
IBM tried to turn Watson, the question-answering system that won Jeopardy! in 2011, into a health care business. It formed Watson Health in 2015 and spent about US$4bn buying health-data companies, including Merge Healthcare and Truven [C01, C02, C03, C04]. Its clinical products, cancer-treatment advice in particular, drew criticism over results and evidence [C13, C14, C15]. A US$62m project at MD Anderson was halted without reaching clinical use [C05, C07], and internal documents reported by STAT described unsafe recommendations in testing; Memorial Sloan Kettering said these were not given to patients, and no adverse events were reported [C10, C11].
IBM cut Watson Health jobs in 2018 and 2020 [C08, C16] and in 2022 sold the unit's data and analytics assets to Francisco Partners, for a price Bloomberg put at more than US$1bn [C17, C18, C19].
The three numbers that matter: about US$4bn spent on acquisitions [C01, C18]; about US$1bn of annual revenue in 2021 with no profit, according to the WSJ via Bloomberg [C16]; and a sale value of more than US$1bn, as Bloomberg reported [C18].
Outcome: classed failure under schema §4.3. The business was exited through the sale of its main assets, and its flagship clinical project was abandoned. The one lesson, as the KB reads it: in a regulated, evidence-driven field, an AI product must be validated on real outcomes before it is marketed at scale.
Outcome: failure
The initiative was abandoned, exited or written down, or an official finding called it a failure.
Basis of the outcome
IBM exited the business by selling Watson Health's data and analytics assets to Francisco Partners in 2022 (S14, S16), after reports, citing unnamed sources, that the unit was unprofitable (S13), at a value Bloomberg reported as more than US$1bn against about US$4bn of acquisitions (S15). The flagship MD Anderson clinical project was terminated in 2016 without clinical use (S04, S05). Under schema §4.3 ('the initiative was abandoned, exited or written down') this is a failure. IBM's statement that it remains committed to Watson and AI (S14), its customer figures (S11) and the continued operation of the sold assets as Merative (S16) are recorded; they do not change the class.
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | Promise after Jeopardy! win | commercial health products in 18–24 months | 2011 | press_reported |
| Before | IBM investment in Watson unit | US$1bn | 2014 | press_reported |
| During | Watson Health formed; Phytel and Explorys bought | Explorys: data on 50m patients, 360 hospitals | Apr 2015 | press_reported |
| During | Merge Healthcare | about US$1bn | Aug 2015 | press_reported |
| During | Truven Health Analytics | US$2.6bn | Feb 2016 | press_reported |
| During | Total acquisitions | about US$4bn (four companies by mid-2016) | 2016 | press_reported |
| During | MD Anderson OEA spending | at least US$62.1m; never in clinical use | 2012–2016 | press_reported |
| During | Concordance with experts (Watson for Oncology) | 73% (Manipal, breast); 49% (Gachon, colon) | as reported 2019 | press_reported |
| During | Organisations using Watson (IBM figure) | about 230 | 2018 | company_reported |
| After | Watson Health revenue / profit | about US$1bn a year; not profitable (unconfirmed) | 2021 | press_reported_unconfirmed |
| After | Sale of assets to Francisco Partners | terms undisclosed; reported at more than US$1bn | Jan 2022 | press_reported_unconfirmed |
| After | Sale completed; Merative formed | 30 Jun 2022 | 2022 | press_reported |
- press_reported
- A journalist's own reporting.
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- press_reported_unconfirmed
- A press figure the company declined to confirm, or one attributed to unnamed observers.
Practices this case bears on
- SupportsWhen the thesis has failed, exit in one decisive move and say what is kept BP-007
- SupportsOutsource only what does not differentiate, and keep the capability to specify, integrate and replace partners BP-017
- SupportsMake bad news safe and fast to reach the top, and act on it BP-022
- SupportsValidate the proposition with the target customers' own evidence and a control-market pilot before a national launch BP-057
Sources
- S01 IBM unveils Watson Health unit, to partner with Apple, Johnson & Johnson, Medtronic, plans acquisitions · Thomas Dworetzky, DOTmed HealthCare Business News, 2015-04-13 · accessed 2026-11-01
- S02 IBM buying Merge Healthcare for $1B to bring medical image analysis to Watson Health · not stated, TechCrunch, 2015-08-06 · accessed 2026-11-01
- S03 IBM Watson Health to buy Truven Health Analytics for $2.6B · not stated, MedCity News, 2016-02-18 · accessed 2026-11-01
- S04 Texas hospital struggles to make IBM's Watson cure cancer · Peter Sayer, Network World, 2017-03-09 · accessed 2026-11-01
- S05 Watson cancer-busting trial on hold after audit report · not stated, The Register, 2017-02-20 · accessed 2026-11-01
- S06 Rometty at HIMSS: what about M.D. Anderson and Watson? · not stated, MedCity News, 2017-02-19 · accessed 2026-11-01
- S07 IBM confirms layoffs at Watson Health · Meg Bryant, Healthcare Dive, 2018-06-07 · accessed 2026-11-01
- S08 IBM Watson Health layoffs reveal deeper problems · Casey Ross, Ike Swetlitz, STAT, 2018-06-11 · accessed 2026-11-01
- S09 Report: IBM Watson delivered unsafe and inaccurate cancer recommendations · Fink Densford, MassDevice, 2018-07-25 · accessed 2026-11-01
- S10 IBM's Watson recommended 'unsafe and incorrect' cancer treatments, STAT reports · not stated, Advisory Board Daily Briefing, 2018-07-27 · accessed 2026-11-01
- S11 IBM responds to recent Watson media coverage · not stated, Healthcare IT News, 2018 (not printed; refers to coverage 'earlier this summer') · accessed 2026-11-01
- S12 How IBM Watson overpromised and underdelivered on AI health care · Eliza Strickland, IEEE Spectrum, 2019-04-02 · accessed 2026-11-01
- S13 IBM is said to consider sale of Watson Health amid cloud focus · Nico Grant, Tom Giles (Bloomberg), Data Center Knowledge (Bloomberg), 2021-02-19 · accessed 2026-11-01
- S14 Francisco Partners to acquire IBM's healthcare data and analytics assets · IBM, IBM Newsroom, 2022-01-21 · accessed 2026-11-01
- S15 IBM sells some Watson Health assets for more than $1 billion · Bloomberg, BNN Bloomberg (Bloomberg), 2022-01-21 · accessed 2026-11-01
- S16 Francisco Partners completes acquisition of IBM Watson Health's data, assets · not stated, Becker's Hospital Review, 2022-07-01 · accessed 2026-11-01
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 1 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

